KAKKIS EMIL D (President & CEO) received a stock award from ULTRAGENYX PHARMACEUTICAL INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 4/20/2026ACC: 0001193125-26-164308
DirectorOfficer· President & CEO
Since Mar 2026
+209.44K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
209.44K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+76.75K
Price / share
—
Trade value
—
% of position
11.6%
4/16/2026
658.99K→735.74K
Total
Net shares
+76.75K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/16/2026 | A · Award | +76.75K | — | — | 11.6% | 658.99K | 735.74K |
| Total | +76.75K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
132.69K shares
Shares
+132.69K
Strike price
24.52
Held after
132.69K
Exercisable
—
4/16/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock132.69K shares | 4/16/2026 | A · Award | +132.69K | 24.52 | — | 132.69K |
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned200K
Common Stock
IndirectShares owned200K
Common Stock
IndirectShares owned1.76M
Total
2.16M indirect2.16M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Common Stock | 200K | Indirect |
| Common Stock | 1.76M | Indirect |
| Total | 2.16M | 2.16M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported